Evidence map›Paper›PMID 36641104›Full record

ArticleMagnetic resonance imaging2023

Prostate cancer lesion detection, volume quantification and high-grade cancer differentiation using cancer risk maps derived from multiparametric MRI with histopathology as the reference standard.

Matthew Gibbons, Jeffry P Simko, Peter R Carroll, Susan M Noworolski

Open access · hybridAbstract read
In one paragraph

Article in Magnetic resonance imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Matthew GibbonsDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States. Electronic address: matthew.gibbons@ucsf.edu.
Jeffry P SimkoDepartment of Urology, University of California, San Francisco, CA, United States; Department of Pathology, University of California, San Francisco, CA, United States. Electronic address: jeff.simko@ucsf.edu.
Peter R CarrollDepartment of Urology, University of California, San Francisco, CA, United States. Electronic address: peter.carroll@ucsf.edu.
Susan M NoworolskiDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States. Electronic address: susan.noworolski@ucsf.edu.
University of California, San Francisco · US

Funding

DCE MRI to Improve Prostate Cancer Identification and CharacterizationR01CA148708 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NOWOROLSKI, SUSAN M · 2010 to 2014
$1.3M
NCI NIH HHS R01 CA148708
6 · The paper itself

Abstract

Multi-parametric MRI (mpMRI) has proven itself a clinically useful tool to assess prostate cancer (PCa). Our objective was to generate PCa risk maps to quantify the volume and location of both all PCa and high grade (Gleason grade group ≥ 3) PCa. Such capabilities would aid physicians and patients in treatment decisions, targeting biopsy, and planning focal therapy. A cohort of men with biopsy proven prostate cancer and pre-prostatectomy mpMRI were studied. PCa and benign ROIs (1524) were identified on mpMRI and histopathology with histopathology serving as the reference standard. Logistic regression models were created to differentiate PCa from benign tissues. The MRI images were registered to ensure correct overlay. The cancer models were applied to each image voxel within prostates to create probability maps of cancer and of high-grade cancer. Use of an optimum probability threshold quantified PCa volume for all lesions >0.1 cc. Accuracies were calculated using area under the curve (AUC) for the receiver operating characteristic (ROC). The PCa models utilized apparent diffusion coefficient (ADC), T2 weighted (T2W), dynamic contrast-enhanced MRI (DCE MRI) enhancement slope, and DCE MRI washout as the statistically significant MRI scans. Application of the PCa maps method provided total PCa volume and individual lesion volumes. The AUCs derived from lesion analysis were 0.91 for all PCa and 0.73 for high-grade PCa. At the optimum threshold, the PCa maps detected 135 / 150 (90%) histopathological lesions >0.1 cc. This study showed the feasibility of cancer risk maps, created from pre-prostatectomy, mpMR images validated with histopathology, to detect PCa lesions >0.1 cc. The method quantified the volume of cancer within the prostate. Method improvements were identified by determining root causes for over and underestimation of cancer volumes. The maps have the potential for improved non-invasive capability in quantitative detection, localization, volume estimation, and MRI characterization of PCa.

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsDiffusion Magnetic Resonance ImagingHumansMagnetic Resonance ImagingMaleProstateReference StandardsRetrospective StudiesDiffusion-weighted imagingDynamic contrast-enhanced imagingHistopathologyMultiparametric MRIProstate cancer

Identifiers

PMID36641104
PMCPMC11229728
OpenAlexW4315641909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.